Abstracts tagged "Anakinra and gout"

Abstract Number: 1291 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Anakinra in Congestive Heart Failure Patients, Including Lvad, with Acute Gouty Arthritis: A Retrospective Study of 36 Patients at an Academic Medical Center
Arash Hassantoufighi¹, Paloma Alejandro², Christopher E. Collins², Florina Constantinescu² and Juhi Bhargava³, ¹Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, washington, DC, ²Rheumatology, MedStar Washington Hospital Center/Georgetown University Medical Center, Washington, DC, ³Internal Medicine, MedStar Washington Hospital Center/Georgetown University Medical Center, washington, DC
Background/Purpose: Gout is the most common inflammatory arthritis worldwide and many patients with gout are ‘complicated’ by multiple comorbidities including metabolic syndrome, renal disease and…
Abstract Number: 1142 • 2017 ACR/ARHP Annual Meeting
A Case Control Study of Anakinra Use for Acute Gout in a VA Patient Cohort Reveals Association with East Asian Descent, High Urate Burden, and Increased Co-Morbidities and All-Cause Mortality
Ena Sharma¹ and Robert Terkeltaub², ¹Rheumatology, University Of California San Diego, San Diego, CA, ²Rheumatology, VA San Diego Healthcare System, San Diego, CA
Background/Purpose: Effectiveness of the IL-1 receptor antagonist anakinra, in resolving flares of acute gout, has been reported in several case series. Here, studying a VA…
Abstract Number: 146 • 2012 ACR/ARHP Annual Meeting
The Treatment of Acute Gouty Arthritis in Complex Hospitalized Patients with Anakinra
Mary Bach¹, Jane Park¹, Pradipta Ghosh¹, Peter A. Simkin² and Gregory C. Gardner³, ¹Rheumatology, University of Washington, Seattle, WA, ²Div of Rheumatology, University of Washington, Seattle, WA, ³Medicine/Rheumatology, University of Washington, Seattle, WA
Background/Purpose: The management of acute crystal-induced arthritis in the hospital setting may be a difficult clinical problem due to co-morbidities that limit the use of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].